Traumatic Brain Injury: From identifying biomarkers to improving clinical trial efficiency
The manifestations and effects of Traumatic Brain Injury (TBI) are varied and impact diverse populations — it is estimated that 69 million individuals suffer TBI each year. A better understanding of how TBI manifests, can lead to better identification of biomarkers, and the development of prevention and treatment strategies. Learn how digital health technologies are shaping the future of TBI clinical research. .
ICON plc is a global provider of outsourced drug development and commercialization solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organizations. Learn more at https://iconplc.com/CNS.